In response to rising healthcare expenditure, governments in developed markets are looking bolster generic uptake in order to contain costs. Physician prescribing by international non-proprietary name (INN), in addition to automatic substitution and pharmacist incentives, are key tools to drive generic uptake.
In the US, despite the addition of many new customers and the continued drive to increase generic uptake as a result of the healthcare reform law, generics companies are set to experience further downward pricing pressures and will be forced to operate with ever-decreasing margins, focusing on consolidation and cost-cutting.
The BRIC countries represent a key growth market for the generics industry. Uptake of generics in these markets will be driven by continued population expansion, increased prosperity, and expanding healthcare coverage.
Your key questions answered
* Evaluate the drivers and resistors to generic uptake in the US, EU, Japan and BRIC markets
* Gain insight into the deal types between companies to bolster their position in generics markets
* Identify which key small molecules are facing patent expiry and provide opportunities for generic producers
Prescription pharmaceuticals sales and growth rate analysis, 2003–15
Operating costs and profit analysis
Shionogi: PharmaVitae forecasts at a glance
Focus on "core strategic" product lines
Late-stage pipeline products Shionogi's launch portfolio consists of 10 products, six of which have already come to market – Cymbalta, Pirespa (pirfenidone), Rapiacta (peramivir), Kapvay (clonidine hydrochloride), and Cuvposa (glycopyrrolate) – indicating its success in launching late-stage products. Furthermore, over 2009–15, Shionogi plans to file New Drug Applications (NDAs) for at least four late-stage pipeline products (S-34957
Copyright©2010 PR Newswire.
All rights reserved